Treatment of essential thrombocythemia with anagrelide.
Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET.
Chintagumpala
M M
MM
Department of Pediatrics, Texas Children's Cancer Center, Houston 77030, USA.
Kennedy
L L
LL
Steuber
C P
CP
D000293:Adolescent; D001772:Blood Cell Count / Q000187:drug effects; D001856:Bone Marrow Examination; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide